Galecto, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Galecto, Inc. (GLTO) is a clinical-stage biotechnology company that develops small-molecule therapeutics targeting galectin modulators and related pathways for the treatment of cancer, fibrosis, severe liver diseases, and hematological malignancies including acute myeloid leukemia, myelofibrosis, and myeloproliferative neoplasms; its pipeline features GB1211, an oral galectin-3 inhibitor in development for non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, and decompensated liver cirrhosis; GB3226, a preclinical dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML; BRM-1420, a dual ENL-YEATS and FLT3 inhibitor licensed in October 2024 for AML; and, following the November 2025 acquisition of Damora Therapeutics, DMR-001, a lead monoclonal antibody targeting mutant calreticulin for essential thrombocythemia and myelofibrosis with Phase 1 proof-of-concept data expected in 2027, alongside DMR-002 and DMR-003 advancing to Phase 1. The Damora acquisition, funded by a concurrent $285 million oversubscribed private placement providing runway into 2029, marks a strategic pivot toward mutCALR-targeted therapies for blood cancers while integrating with Galecto's oncology assets including GB3226 featured at the 2025 ASH Annual Meeting. Founded in 2011 and headquartered in Copenhagen, Denmark, Galecto operates primarily in the U.S. and Europe, serving patients with unmet needs in oncology and fibrotic conditions through its Nasdaq-listed structure.
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
Galecto Announces Pricing of $275 Million Underwritten Public Offering
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
Galecto (NASDAQ:GLTO) Shares Down 13.3% – Time to Sell?
Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GLTO, MOVE: two penny stocks quadrupled today – but should you buy?
Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029
Galecto Announces Acquisition of Damora Therapeutics
Galecto Reports Third Quarter 2025 Operating and Financial Results
What's Going On With Nano-Cap Galecto Stock On Tuesday?
Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble
Galecto Reports Second Quarter 2025 Operating and Financial Results
12,701 Shares in Galecto, Inc. (NASDAQ:GLTO) Bought by Squarepoint Ops LLC
Galecto Reports First Quarter 2025 Operating and Financial Results
Galecto Reports Full-Year 2024 Financial Results